CCR10

Summary

CCR10 (C-C motif chemokine receptor 10, HGNC:4474) is a protein-coding gene on chromosome 17q21.2, encoding C-C chemokine receptor type 10 (P46092). Receptor for chemokines SCYA27 and SCYA28.

Chemokines are a group of small (approximately 8 to 14 kD), mostly basic, structurally related molecules that regulate cell trafficking of various types of leukocytes through interactions with a subset of 7-transmembrane, G protein-coupled receptors. Chemokines also play fundamental roles in the development, homeostasis, and function of the immune system, and they have effects on cells of the central nervous system as well as on endothelial cells involved in angiogenesis or angiostasis. Chemokines are divided into 2 major subfamilies, CXC and CC, based on the arrangement of the first 2 of the 4 conserved cysteine residues; the 2 cysteines are separated by a single amino acid in CXC chemokines and are adjacent in CC chemokines. CCR10 is the receptor for CCL27 (SCYA27; MIM 604833); CCR10-CCL27 interactions are involved in T cell-mediated skin inflammation (Homey et al., 2002 [PubMed 11821900]).

Source: NCBI Gene 2826 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 44 total
• Druggable target: yes
• MANE Select transcript: NM_016602

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4474
Approved symbol	CCR10
Name	C-C motif chemokine receptor 10
Location	17q21.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000184451
Ensembl biotype	protein_coding
OMIM	600240
Entrez	2826

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000332438, ENST00000591568, ENST00000591765

RefSeq mRNA: 1 — MANE Select: NM_016602 NM_016602

CCDS: CCDS11435

Canonical transcript exons

ENST00000332438 — 2 exons

Exon	Start	End
ENSE00001324962	42678889	42680617
ENSE00001407622	42681800	42681843

Expression profiles

Bgee: expression breadth ubiquitous, 173 present calls, max score 87.17.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4142 / max 42.5205, expressed in 182 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166181	0.2133	88
166182	0.1152	55
166183	0.0856	31

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	87.17	gold quality
pituitary gland	UBERON:0000007	82.78	gold quality
adenohypophysis	UBERON:0002196	82.14	gold quality
right hemisphere of cerebellum	UBERON:0014890	77.91	gold quality
cerebellar hemisphere	UBERON:0002245	77.29	gold quality
cerebellar cortex	UBERON:0002129	77.22	gold quality
body of uterus	UBERON:0009853	76.29	gold quality
cerebellum	UBERON:0002037	75.97	gold quality
left uterine tube	UBERON:0001303	75.32	gold quality
apex of heart	UBERON:0002098	74.63	gold quality
endocervix	UBERON:0000458	73.63	gold quality
left ovary	UBERON:0002119	72.92	gold quality
right ovary	UBERON:0002118	72.90	gold quality
tibial nerve	UBERON:0001323	72.80	gold quality
gastrocnemius	UBERON:0001388	72.77	gold quality
primary visual cortex	UBERON:0002436	72.34	gold quality
right atrium auricular region	UBERON:0006631	72.26	gold quality
right coronary artery	UBERON:0001625	72.07	gold quality
lower esophagus muscularis layer	UBERON:0035833	72.07	gold quality
muscle layer of sigmoid colon	UBERON:0035805	72.06	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	72.06	gold quality
lower esophagus	UBERON:0013473	71.98	gold quality
right frontal lobe	UBERON:0002810	71.52	gold quality
muscle of leg	UBERON:0001383	71.42	gold quality
left coronary artery	UBERON:0001626	71.19	gold quality
mucosa of stomach	UBERON:0001199	71.06	gold quality
descending thoracic aorta	UBERON:0002345	70.91	gold quality
cardiac atrium	UBERON:0002081	70.76	gold quality
tibial artery	UBERON:0007610	70.69	gold quality
popliteal artery	UBERON:0002250	70.68	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-88	yes	106.80
E-MTAB-8410	yes	35.37
E-HCAD-11	yes	25.71
E-ANND-3	yes	6.68

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

10 targeting CCR10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-12130	99.75	65.47	452
HSA-MIR-3940-5P	99.14	65.26	493
HSA-MIR-4507	99.14	65.27	515
HSA-MIR-6809-5P	99.13	68.45	1223
HSA-MIR-4716-5P	98.82	68.57	1168
HSA-MIR-6781-3P	97.44	66.85	970
HSA-MIR-2114-5P	96.00	64.56	617

Literature-anchored findings (GeneRIF, showing 24)

• CCR10 and its ligand CCL27 may contribute to the skin infiltration of malignant T-cells in cutaneous T-cell lymphoma. (PMID:15700309)
• gene expression of CCR10 was increased by recombinant ANXA1 and the N-terminal ANXA1 peptide (PMID:16460738)
• CCR10-CTACK/CCL27 interactions between circulating T cells and keratinocytes would seem to play an important role in the pathophysiology of mycosis fungoides. (PMID:16675558)
• CCR10 allows T regulatory (Treg) cells recruited to chronically inflamed liver tissues to respond to CCL28 secreted by epithelial cells, resulting in the accumulation of CCR10+ Tregs at mucosal surfaces. (PMID:16785557)
• CCR4 and CCR10 may play an important role in ATLL invasion into the skin (PMID:17071491)
• CCR4 and CCR10 are expressed on epidermal keratinocytes and that both are functional in terms of skin cytokine production and/or migration to their ligand CCL17 and CCL27, respectively. (PMID:18782672)
• TLR2 ligands induce CCR9 and CCR10 expression by circulating B-cells and increase their chemotaxis. TLR2 stimulation also induced J chain and IgA production demonstrating the induction of mucosal-like antibody secreting cells. (PMID:20947433)
• The high fraction of circulating IgA+ and IgG+ B cells expressing CCR9 and CCR10 in the first months of life indicates activation of naive B cells in the gut, coinciding with bacterial colonization. (PMID:21075690)
• unlike blood plasmacytoid dendritic cells (pDCs), a subset of tonsil pDCs express functional CCR6 and CCR10, and their respective ligands CCL20 and CCL27 are detected in inflamed epithelia (PMID:21937703)
• CCR7 overexpression correlated with expression of metallothionein, while CCR10 was associated with cerebral metastases. CCR7 and CCR10 overexpressions were associated with a worse outcome independent of Breslow’s tumor thickness and Clark level. (PMID:22350183)
• low CCL27/CCR10 and CXCL12/CXCR4 intratumoral mRNA ratios are associated with melanoma progression (PMID:22526457)
• Findings support the notion that CCR10 and its ligand CCL27 may contribute to the skin infiltration of malignant T-cells in mycosis fungoides and adult T-cell leukemia/lymphoma. (PMID:24970722)
• The chemokine receptor CCR10 is highly expressed in human glioblastoma compared with control brain tissue. (PMID:25149529)
• CCR10/CCL27 crosstalk mediated drug resistance, contributing to failure of proteasome-inhibitors in multiple myeloma. (PMID:27732933)
• CCL27 drives baseline recruitment of Herpes simplex virus-specific CD8 T cells expressing CCR10, while interferon-responsive CXCR3 ligands recruit additional cells in response to virus-driven inflammation. (PMID:28701399)
• CCR10 may be a key regulator in breast cancer cell invasion and migration (PMID:28830025)
• Inflammation-induced TNF promotes hepatocellular CCR10 expression and downstream PI3K/Akt-mediated hepatocarcinogenesis. (PMID:29445190)
• The characterization of CCR10(+) ILC2s in human samples and in mouse asthma models suggests that these cells downregulate allergic inflammation through IFN-gamma production. (PMID:30475388)
• Coordinated co-migration of CCR10(+) antibody-producing B cells with helper T cells for colonic homeostatic regulation. (PMID:32773769)
• SARS-CoV2 pneumonia recovery is linked to expansion of innate lymphoid cells type 2 expressing CCR10. (PMID:34564853)
• Inhibition of CCL28/CCR10-Mediated eNOS Downregulation Improves Skin Wound Healing in the Obesity-Induced Mouse Model of Type 2 Diabetes. (PMID:35899992)
• The CCL27-CCR10 axis contributes to promoting proliferation, migration, and invasion of lung squamous cell carcinoma. (PMID:36169116)
• Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa. (PMID:37222480)
• Inhibition of cc chemokine receptor 10 ameliorates osteoarthritis via inhibition of the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin pathway. (PMID:38429844)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccr10	ENSDARG00000040643
mus_musculus	Ccr10	ENSMUSG00000044052
rattus_norvegicus	Ccr10	ENSRNOG00000020275

Paralogs (23): CCR6 (ENSG00000112486), CCRL2 (ENSG00000121797), CCR2 (ENSG00000121807), CXCR4 (ENSG00000121966), CCR7 (ENSG00000126353), ACKR4 (ENSG00000129048), ACKR3 (ENSG00000144476), ACKR2 (ENSG00000144648), RGR (ENSG00000148604), CXCR5 (ENSG00000160683), CCR5 (ENSG00000160791), CXCR1 (ENSG00000163464), CCR1 (ENSG00000163823), CX3CR1 (ENSG00000168329), CXCR6 (ENSG00000172215), XCR1 (ENSG00000173578), CCR9 (ENSG00000173585), CCR8 (ENSG00000179934), CXCR2 (ENSG00000180871), GALR2 (ENSG00000182687), CCR3 (ENSG00000183625), CCR4 (ENSG00000183813), CXCR3 (ENSG00000186810)

Protein

Protein identifiers

C-C chemokine receptor type 10 — P46092 (reviewed: P46092)

Alternative names: G-protein coupled receptor 2

All UniProt accessions (3): P46092, K7EPC9, K7ER70

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for chemokines SCYA27 and SCYA28. Subsequently transduces a signal by increasing the intracellular calcium ions level and stimulates chemotaxis in a pre-B cell line.

Subcellular location. Cell membrane.

Tissue specificity. Expressed at high levels in adult testis, small intestine, fetal lung, fetal kidney. Weaker expression was observed in many other adult tissues including spleen, thymus, lymph node, Peyer patches, colon, heart, ovary, peripheral blood lymphocytes, thyroid and spinal cord. Also expressed by melanocytes, dermal fibroblasts, dermal microvascular endothelial cells. Also detected in T-cells and in skin-derived Langerhans cells.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_057686* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR000355	Chemokine_rcpt	Family
IPR005382	Chemokine_CCR10	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR050119	CCR1-9-like	Family

Pfam: PF00001

UniProt features (23 total): topological domain 8, transmembrane region 7, sequence conflict 3, compositionally biased region 2, chain 1, region of interest 1, disulfide bond 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P46092-F1	76.61	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 113–191

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-380108	Chemokine receptors bind chemokines
R-HSA-418594	G alpha (i) signalling events
R-HSA-162582	Signal Transduction
R-HSA-372790	Signaling by GPCR
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)
R-HSA-375276	Peptide ligand-binding receptors
R-HSA-388396	GPCR downstream signalling
R-HSA-500792	GPCR ligand binding

MSigDB gene sets: 115 (showing top): AHRARNT_01, GOBP_CELL_CHEMOTAXIS, GOBP_RESPONSE_TO_PEPTIDE, GOCC_CELL_SURFACE, GAURNIER_PSMD4_TARGETS, GOBP_TAXIS, REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS, CCANNAGRKGGC_UNKNOWN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, BLALOCK_ALZHEIMERS_DISEASE_UP, GGGNNTTTCC_NFKB_Q6_01, HAHTOLA_SEZARY_SYNDROM_UP, MAF_Q6, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, NERF_Q2

GO Biological Process (8): immune response (GO:0006955), G protein-coupled receptor signaling pathway (GO:0007186), positive regulation of cytosolic calcium ion concentration (GO:0007204), calcium-mediated signaling (GO:0019722), cell chemotaxis (GO:0060326), chemotaxis (GO:0006935), signal transduction (GO:0007165), chemokine-mediated signaling pathway (GO:0070098)

GO Molecular Function (5): G protein-coupled receptor activity (GO:0004930), C-C chemokine receptor activity (GO:0016493), C-C chemokine binding (GO:0019957), chemokine receptor activity (GO:0004950), protein binding (GO:0005515)

GO Cellular Component (5): endoplasmic reticulum (GO:0005783), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Signaling by GPCR	2
Peptide ligand-binding receptors	1
GPCR downstream signalling	1
Signal Transduction	1
GPCR ligand binding	1
Class A/1 (Rhodopsin-like receptors)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor signaling pathway	2
chemokine binding	2
cellular anatomical structure	2
immune system process	1
response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
regulation of biological quality	1
intracellular signaling cassette	1
chemotaxis	1
cell migration	1
cellular response to chemical stimulus	1
response to chemical	1
taxis	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cytokine-mediated signaling pathway	1
cellular response to chemokine	1
transmembrane signaling receptor activity	1
chemokine receptor activity	1
C-C chemokine binding	1
G protein-coupled chemoattractant receptor activity	1
cytokine receptor activity	1
chemokine-mediated signaling pathway	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1

Protein interactions and networks

STRING

906 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCR10	CCL27	Q9Y4X3	999
CCR10	CCL17	Q92583	978
CCR10	CCL22	O00626	904
CCR10	CCL21	O00585	903
CCR10	CCL28	Q9NRJ3	882
CCR10	CXCL12	P48061	783
CCR10	CCR1	P32246	765
CCR10	CCL20	P78556	761
CCR10	MADCAM1	Q13477	756
CCR10	CCL1	P22362	735
CCR10	CCL5	P13501	735
CCR10	CCL2	P13500	715
CCR10	CD4	P01730	711
CCR10	CCR7	P32248	694
CCR10	CCR2	P41597	686

IntAct

17 interactions, top by confidence:

A	B	Type	Score
CCR10	S100A10	psi-mi:“MI:2364”(proximity)	0.630
CCR10	S100A10	psi-mi:“MI:0407”(direct interaction)	0.630
ARPC3	CCR10	psi-mi:“MI:0915”(physical association)	0.560
CCR10	ANXA2	psi-mi:“MI:2364”(proximity)	0.420
CCR10	ANXA2	psi-mi:“MI:0914”(association)	0.420
FYN	CCR10	psi-mi:“MI:0915”(physical association)	0.400
GRB2	CCR10	psi-mi:“MI:0915”(physical association)	0.400
NCK1	CCR10	psi-mi:“MI:0915”(physical association)	0.400
CCR10	ACTB	psi-mi:“MI:0403”(colocalization)	0.380
CCR10	ACTB	psi-mi:“MI:2364”(proximity)	0.380
CCR10	S100A10	psi-mi:“MI:0914”(association)	0.350
ARPC3	CCR10	psi-mi:“MI:0915”(physical association)	0.000
PRRC2A	CCR10	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (3): CCR10 (Two-hybrid), CCR10 (Affinity Capture-RNA), CCR10 (Two-hybrid)

ESM2 similar proteins: A0A6I8PUB9, O00155, O00270, O14842, O14843, O15529, O43603, O46685, O60755, O88626, O88634, O88853, O88854, O88855, P0C5I1, P46092, P46093, P50132, Q149R9, Q15722, Q15743, Q1JQB3, Q3T181, Q3UFD7, Q3ZC80, Q4KLH9, Q6XKD3, Q76JU8, Q76JU9, Q76JV1, Q86VZ1, Q8BUD0, Q8BYC4, Q8HYC3, Q8K3T4, Q8TDS5, Q8TDU9, Q920E0, Q924U0, Q96G91

Diamond homologs: A0A4W3GG95, A0A6I8PUB9, B2GV46, B5X337, D4A7K7, E7FEL0, E9QJ73, F8VQN3, O00270, O08726, O08858, O14842, O14843, O15529, O42179, O43603, O46685, O60755, O77408, O88410, O88626, O88634, O88853, P21109, P23944, P25024, P25025, P35344, P35383, P35414, P41231, P41232, P46092, P46093, P49652, P49682, P49683, P50132, P51675, P51679

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

2241 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:42680237:G:C	S135R	0.997
17:42680237:G:T	S135R	0.997
17:42680239:T:G	S135R	0.997
17:42679874:G:C	F256L	0.993
17:42679874:G:T	F256L	0.993
17:42679876:A:G	F256L	0.993
17:42680550:C:G	C31S	0.992
17:42680551:A:T	C31S	0.992
17:42680058:A:C	F195C	0.991
17:42679857:G:T	P262H	0.989
17:42680465:A:C	N59K	0.989
17:42680465:A:T	N59K	0.989
17:42679994:G:C	F216L	0.988
17:42679994:G:T	F216L	0.988
17:42679996:A:G	F216L	0.988
17:42680379:T:A	D88V	0.988
17:42679692:A:C	F317C	0.987
17:42680543:C:A	K33N	0.987
17:42680543:C:G	K33N	0.987
17:42680550:C:T	C31Y	0.987
17:42679691:G:C	F317L	0.986
17:42679691:G:T	F317L	0.986
17:42679693:A:G	F317L	0.986
17:42680146:A:G	W166R	0.986
17:42680146:A:T	W166R	0.986
17:42679724:A:C	N306K	0.985
17:42679724:A:T	N306K	0.985
17:42679850:G:C	S264R	0.985
17:42679850:G:T	S264R	0.985
17:42679852:T:G	S264R	0.985

dbSNP variants (sampled 300 via entrez): RS1000284310 (17:42678731 C>A,T), RS1001097202 (17:42680678 G>A), RS1001277959 (17:42680357 C>G), RS1002087060 (17:42679337 G>T), RS1002695110 (17:42681018 T>A), RS1003292726 (17:42682605 T>C,G), RS1004998048 (17:42683254 A>T), RS1005121408 (17:42682955 C>A,G,T), RS1006745061 (17:42680735 G>A,C), RS1007139911 (17:42679695 C>A,G,T), RS1008094184 (17:42681123 C>A,G), RS1008679870 (17:42682629 G>A,C), RS1009087759 (17:42682225 A>C), RS1009752891 (17:42681751 T>A), RS1010539667 (17:42682622 A>G)

Disease associations

OMIM: gene MIM:600240 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2321628 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Chemokine receptors

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
BI-6901	Antagonist	9.0	pIC50

ChEMBL bioactivities

68 potent at pChembl≥5 of 69 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.40	IC50	0.3981	nM	CHEMBL3889627
9.00	IC50	1	nM	CHEMBL3889627
8.90	IC50	1.259	nM	CHEMBL3889627
8.70	IC50	1.995	nM	CHEMBL3889627
8.70	IC50	1.995	nM	CHEMBL3951018
8.50	IC50	3.162	nM	CHEMBL3951018
8.47	IC50	3.4	nM	CHEMBL3951018
8.10	IC50	7.943	nM	CHEMBL3923733
8.10	IC50	7.943	nM	CHEMBL3904154
8.00	IC50	10	nM	CHEMBL3971826
8.00	IC50	10	nM	CHEMBL3891692
8.00	IC50	10	nM	CHEMBL3889627
7.90	IC50	12.59	nM	CHEMBL3971886
7.90	IC50	12.59	nM	CHEMBL3951018
7.80	IC50	15.85	nM	CHEMBL3951018
7.80	IC50	15.85	nM	CHEMBL3923733
7.70	IC50	19.95	nM	CHEMBL3951018
7.70	IC50	19.95	nM	CHEMBL3918664
7.60	IC50	25.12	nM	CHEMBL3909737
7.60	IC50	25.12	nM	CHEMBL3889627
7.40	IC50	39.81	nM	CHEMBL3959737
7.30	IC50	50.12	nM	CHEMBL3975141
7.30	IC50	50.12	nM	CHEMBL3908230
7.28	IC50	53	nM	CHEMBL3908230
7.20	IC50	63.1	nM	CHEMBL3919363
7.20	IC50	63.1	nM	CHEMBL3960764
7.20	IC50	63.1	nM	CHEMBL3890608
7.10	IC50	79.43	nM	CHEMBL3933303
7.00	IC50	100	nM	CHEMBL3933303
6.90	IC50	125.9	nM	CHEMBL3891289
6.90	IC50	125.9	nM	CHEMBL3945769
6.90	IC50	125.9	nM	CHEMBL3960700
6.80	IC50	158.5	nM	CHEMBL3969321
6.80	IC50	158.5	nM	CHEMBL3951018
6.70	IC50	199.5	nM	CHEMBL3971886
6.60	IC50	251.2	nM	CHEMBL3979967
6.60	IC50	251.2	nM	CHEMBL3942284
6.60	IC50	251.2	nM	CHEMBL3901006
6.60	IC50	251.2	nM	CHEMBL3964547
6.60	IC50	251.2	nM	CHEMBL3908230
6.40	IC50	398.1	nM	CHEMBL3946799
6.36	IC50	440	nM	CHEMBL4168948
6.30	IC50	501.2	nM	CHEMBL3951650
6.30	IC50	501.2	nM	CHEMBL3964547
6.30	IC50	501.2	nM	CHEMBL3908983
6.30	IC50	501.2	nM	CHEMBL3926111
6.20	IC50	631	nM	CHEMBL3908230
6.20	IC50	631	nM	CHEMBL3926111
6.20	IC50	631	nM	CHEMBL3955499
6.16	IC50	690	nM	CHEMBL3908230

PubChem BioAssay actives

68 with measured affinity, of 96 total; 38 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]-1H-indole-4-sulfonamide	1323906: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of CCL27-dependent calcium flux in presence of coelenterazine H by FLIPR assay	ic50	0.0004	uM
4-amino-3,5-dichloro-N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323906: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of CCL27-dependent calcium flux in presence of coelenterazine H by FLIPR assay	ic50	0.0020	uM
4-amino-3,5-dichloro-N-[(2R)-4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0079	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]-1H-indole-6-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0079	uM
N-[4-(2-cyanopyrrol-1-yl)-1-oxo-1-[4-(trifluoromethyl)piperidin-1-yl]butan-2-yl]-1H-indole-4-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0100	uM
N-[4-(2-cyanopyrrol-1-yl)-1-oxo-1-piperidin-1-ylbutan-2-yl]-1H-indole-4-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0100	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]-1H-indole-5-sulfonamide	1323904: Antagonist activity at human CCR10 expressed in mouse BA/F3 cells assessed as inhibition of human CCL27-dependent chemotaxis	ic50	0.0126	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(2-methylpiperidin-1-yl)-1-oxobutan-2-yl]-1H-indole-4-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0199	uM
N-[1-(azepan-1-yl)-4-(2-cyanopyrrol-1-yl)-1-oxobutan-2-yl]-1H-indole-4-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0251	uM
2-amino-4,6-dichloro-N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0398	uM
4-amino-3,5-dichloro-N-[1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323904: Antagonist activity at human CCR10 expressed in mouse BA/F3 cells assessed as inhibition of human CCL27-dependent chemotaxis	ic50	0.0501	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]naphthalene-1-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0501	uM
4-amino-3,5-dichloro-N-[4-(5-cyanopyrazol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0631	uM
4-amino-2,5-dichloro-N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0631	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(3-methylpiperidin-1-yl)-1-oxobutan-2-yl]-1H-indole-4-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.0631	uM
3-amino-N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]-2,4-dimethylbenzenesulfonamide	1323904: Antagonist activity at human CCR10 expressed in mouse BA/F3 cells assessed as inhibition of human CCL27-dependent chemotaxis	ic50	0.0794	uM
4-amino-3,5-dichloro-N-[4-(2-chlorophenyl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.1259	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]-1-methylindole-4-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.1259	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(4-hydroxypiperidin-1-yl)-1-oxobutan-2-yl]-1H-indole-4-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.1259	uM
4-amino-3,5-dichloro-N-[4-(2-cyanopyrrol-1-yl)-1-oxo-1-piperidin-1-ylbutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.1585	uM
4-amino-N-[1-(azepan-1-yl)-4-(2-cyanopyrrol-1-yl)-1-oxobutan-2-yl]-3,5-dichlorobenzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.2512	uM
4-amino-3,5-dichloro-N-[4-(2-chloroimidazol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323904: Antagonist activity at human CCR10 expressed in mouse BA/F3 cells assessed as inhibition of human CCL27-dependent chemotaxis	ic50	0.2512	uM
4-amino-3,5-dichloro-N-[4-(5-chloropyrazol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.2512	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]-1H-indole-7-sulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.2512	uM
4-amino-3,5-dichloro-N-[4-(2-cyanopyrrol-1-yl)-1-oxo-1-[4-(trifluoromethyl)piperidin-1-yl]butan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.3981	uM
methyl (2S)-1-[(2R)-2-[methyl-[(2S)-2-[[(2S)-4-methyl-2-[methyl-[2-[[(2S)-1-[(2R,3S)-3-methyl-2-[(E)-3-phenylprop-2-enoyl]oxypentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylate	1350790: Antagonist activity at human CCR10 expressed in human U2OS cells assessed as inhibition of CCL27-induced beta-arrestin recruitment pre-incubated for 30 mins before CCL27 stimulation for 90 or 180 mins by chemiluminescence method	ic50	0.4400	uM
4-amino-3,5-dichloro-N-[(2R)-1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.5012	uM
4-amino-3,5-dichloro-N-[(2R)-1-(4-methylpiperidin-1-yl)-1-oxo-4-phenylbutan-2-yl]benzenesulfonamide	1323904: Antagonist activity at human CCR10 expressed in mouse BA/F3 cells assessed as inhibition of human CCL27-dependent chemotaxis	ic50	0.5012	uM
4-amino-3,5-dichloro-N-[4-(2-cyanoimidazol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.5012	uM
4-amino-3,5-dichloro-N-[4-(2-cyanopyrrol-1-yl)-1-(3-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.6310	uM
4-amino-3,5-dichloro-N-[4-(2-cyanopyrrol-1-yl)-1-(2-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	0.7943	uM
4-amino-3,5-dichloro-N-[1-(4-methylpiperidin-1-yl)-1-oxo-4-(triazol-2-yl)butan-2-yl]benzenesulfonamide	1323904: Antagonist activity at human CCR10 expressed in mouse BA/F3 cells assessed as inhibition of human CCL27-dependent chemotaxis	ic50	1.2589	uM
4-amino-3,5-dichloro-N-[1-(4-methylpiperidin-1-yl)-1-oxo-4-pyrazol-1-ylbutan-2-yl]benzenesulfonamide	1323904: Antagonist activity at human CCR10 expressed in mouse BA/F3 cells assessed as inhibition of human CCL27-dependent chemotaxis	ic50	1.2589	uM
N-[4-(2-cyanopyrrol-1-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	1.2589	uM
methyl (2S)-1-[(2R)-2-[methyl-[(2S)-2-[[(2S)-4-methyl-2-[methyl-[2-[[(2S)-1-[(2R,3S)-3-methyl-2-[(Z)-3-phenylprop-2-enoyl]oxypentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylate	1350790: Antagonist activity at human CCR10 expressed in human U2OS cells assessed as inhibition of CCL27-induced beta-arrestin recruitment pre-incubated for 30 mins before CCL27 stimulation for 90 or 180 mins by chemiluminescence method	ic50	2.7100	uM
methyl (2S)-1-[(2R)-2-[methyl-[(2S)-2-[[(2S)-4-methyl-2-[methyl-[2-[[(2S)-1-[(2R,3S)-3-methyl-2-(3-phenylpropanoyloxy)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylate	1350790: Antagonist activity at human CCR10 expressed in human U2OS cells assessed as inhibition of CCL27-induced beta-arrestin recruitment pre-incubated for 30 mins before CCL27 stimulation for 90 or 180 mins by chemiluminescence method	ic50	3.1400	uM
4-(2-cyanopyrrol-1-yl)-2-(1H-indol-4-ylsulfonylamino)-N,N-dimethylbutanamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	3.9811	uM
4-amino-3,5-dichloro-N-[1-(4-methylpiperidin-1-yl)-1-oxo-4-pyrrol-1-ylbutan-2-yl]benzenesulfonamide	1323903: Antagonist activity at human CCR10 expressed in CHOK1 cells coexpressing aequorin/Galphaq assessed as inhibition of human CCL27-dependent calcium flux in presence of coelenterazine H by chemiluminescence assay	ic50	3.9811	uM

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression	1
entinostat	increases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation	1
Benzo(a)pyrene	decreases methylation	1
Calcium	affects abundance	1
Cisplatin	decreases expression	1
Lipopolysaccharides	increases expression, affects cotreatment	1
Niclosamide	increases expression	1
Smoke	decreases expression	1
Aflatoxin B1	decreases methylation	1
Acrylamide	increases expression	1

ChEMBL screening assays

25 unique, capped per target: 16 functional, 9 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2328027	Binding	Antagonist activity at CCR10 (unknown origin) assessed as inhibition of chemotaxis at 10 uM	1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists. — Bioorg Med Chem Lett
CHEMBL2328619	Functional	Antagonist activity at CCR10 (unknown origin) assessed as inhibition of calcium flux at 10 uM	1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists. — Bioorg Med Chem Lett

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KU88	cAMP Hunter CHO-K1 CCR10 Gi	Spontaneously immortalized cell line	Female
CVCL_KZ92	PathHunter U2OS CCR10 Activated GPCR Internalization	Cancer cell line	Female
CVCL_KZ93	PathHunter U2OS CCR10 beta-arrestin	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.